



**Clinical Policy: Adalimumab (Humira), Adalimumab-atto (Amjevita), Adalimumab-adbm (Cyltezo), Adalimumab-bwwd (Hadlima), Adalimumab-adaz (Hyrimoz)**

Reference Number: IN.PHAR.242

Effective Date: 08.16

Last Review Date: 10.22

Line of Business: Medicaid

[Coding Implications](#)

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

**Description**

Adalimumab (Humira<sup>®</sup>), adalimumab-atto (Amjevita<sup>™</sup>), adalimumab-adbm (Cyltezo<sup>™</sup>), adalimumab-bwwd (Hadlima<sup>™</sup>), and adalimumab-adaz (Hyrimoz<sup>™</sup>) are tumor necrosis factor (TNF) blockers.

**FDA Approved Indication(s)**

Indications	Description	Humira	Amjevita, Cyltezo, Hadilma, Hyrimoz
Rheumatoid arthritis (RA)	Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active RA	X	X
Juvenile idiopathic arthritis (JIA)	Reducing signs and symptoms of moderately to severely active polyarticular JIA (PJIA) in patients 2 (Humira) or 4 (Amjevita) years of age and older	X	X
Psoriatic arthritis (PsA)	Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active PsA	X	X
Ankylosing spondylitis (AS)	Reducing signs and symptoms in adult patients with active AS	X	X
Adult Crohn's disease (CD)	Reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active CD who have had an inadequate response to conventional therapy; reducing signs and symptoms and inducing clinical remission in these patients if they have also lost response to or are intolerant to infliximab (products)	X	X
Pediatric CD	Reducing signs and symptoms and inducing and maintaining clinical remission in patients 6 years of age and older with moderately to severely active	X	—

Indications	Description	Humira	Amjevita, Cyltezo, Hadlima, Hyrimoz
	CD who have had an inadequate response to corticosteroids or immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate (MTX)		
Adult ulcerative colitis (UC)	Inducing and sustaining clinical remission in adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to immunosuppressants such as corticosteroids, azathioprine or 6-mercaptopurine (6-MP). The effectiveness of adalimumab products has not been established in patients who have lost response to or were intolerant to TNF blockers	X	X
Pediatric UC	Treatment of moderately to severely active UC in pediatric patients 5 years of age and older	X	–
Plaque psoriasis (PsO)	The treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate	X	X
Hidradenitis suppurativa (HS)	The treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older	X	–
Uveitis (UV)	The treatment of non-infectious intermediate, posterior and panuveitis in adults and pediatric patients 2 years of age and older	X	–

**Policy/Criteria**

*Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.*

It is the policy of health plans affiliated with Centene Corporation® that Humira, Amjevita, Cyltezo, Hadlima, and Hyrimoz are **medically necessary** when the following criteria are met:

**I. Initial Approval Criteria**

**A. Ankylosing Spondylitis** (must meet all):

1. Dose does not exceed 40 mg every other week.

**Approval duration: 12 months**

**B. Crohn’s Disease** (must meet all):

1. ;Member meets one of the following (a or b):
  - a. Failure of a  $\geq 3$  consecutive month trial of at least ONE immunomodulator (e.g., azathioprine, 6-mercaptopurine [6-MP], MTX) at up to maximally indicated

- doses, unless contraindicated or clinically significant adverse effects are experienced;
- b. Medical justification supports inability to use immunomodulators (*see Appendix E*);
2. Dose does not exceed one of the following (a or b):
    - a. Adults: 160 mg on Day 1 and 80 mg on Day 15, followed by maintenance dose of 40 mg every other week starting Day 29;
    - b. Pediatrics (i or ii):
      - i. Weight 17 kg (37 lbs.) to < 40 kg (88 lbs.): 80 mg on Day 1 and 40 mg on Day 15, followed by maintenance dose of 20 mg every other week starting Day 29;
      - ii. Weight  $\geq$  40 kg (88 lbs): 160 mg on Day 1 and 80 mg on Day 15, followed by maintenance dose of 40 mg every other week starting Day 29.

**Approval duration: 12 months**

**C. Hidradenitis Suppurativa :**

1. Failure of at least TWO of the following, each tried for  $\geq$  3 consecutive months from different therapeutic classes, at up to maximally indicated doses, unless clinically significant adverse effects are experienced or all are contraindicated:
  - a. Systemic antibiotic therapy (e.g., clindamycin, minocycline, doxycycline, rifampin);
  - b. Oral retinoids (e.g., acitretin, isotretinoin);
  - c. Hormonal treatment (e.g., estrogen-containing combined oral contraceptives, spironolactone);
2. Dose does not exceed 160 mg on Day 1 and 80 mg on Day 15, followed by maintenance dose of 40 mg every week starting Day 29.

**Approval duration: 12 months**

**D. Plaque Psoriasis (must meet all):**

1. Diagnosis of moderate-to-severe PsO
2. Member meets one of the following (a or b):
  - a. Failure of a  $\geq$  3 consecutive month trial of MTX at up to maximally indicated doses;
  - b. Member has intolerance or contraindication to MTX (*see Appendix D*), and failure of a  $\geq$  3 consecutive month trial of cyclosporine or acitretin at up to maximally indicated doses, unless clinically significant adverse effects are experienced or both are contraindicated;
3. Failure of a  $\geq$  3 consecutive month trial of Taltz<sup>®</sup>, unless contraindicated or clinically significant adverse effects are experienced;  
*\*Prior authorization may be required for Taltz*
4. Dose does not exceed 80 mg initial dose, followed by maintenance dose of 40 mg every other week starting one week after initial dose.

**Approval duration: 12 months**

**E. Polyarticular Juvenile Idiopathic Arthritis (must meet all):**

1. Diagnosis of PJIA as evidenced by  $\geq$  5 joints with active arthritis;

2. Dose does not exceed one of the following (a, b, or c):
  - a. Weight 10 kg (22 lbs) to <15 kg (33 lbs): 10 mg every other week;
  - b. Weight 15 kg (33 lbs) to < 30 kg (66 lbs): 20 mg every other week;
  - c. Weight  $\geq$  30 kg (66 lbs): 40 mg every other week.

**Approval duration: 12 months**

**F. Psoriatic Arthritis** (must meet all):

1. Diagnosis of PsA;
2. Dose does not exceed 40 mg every other week.

**Approval duration: 12 months**

**G. Rheumatoid Arthritis** (must meet all):

1. Member meets one of the following (a or b):
  - a. Failure of a  $\geq$  3 consecutive month trial of MTX at up to maximally indicated doses;
  - b. Member has intolerance or contraindication to MTX (*see Appendix D*), and failure of a  $\geq$  3 consecutive month trial of at least ONE conventional disease-modifying antirheumatic drug [DMARD] (e.g., sulfasalazine, leflunomide, hydroxychloroquine) at up to maximally indicated doses, unless contraindicated or clinically significant adverse effects are experienced;
2. Failure of at least one of the following, used for  $\geq$  3 consecutive months, unless contraindicated or clinically significant adverse effects are experienced: Enbrel<sup>®</sup>, Kevzara<sup>®</sup>, Xeljanz<sup>®</sup>/Xeljanz XR<sup>®</sup>;  
*\*Prior authorization may be required for Enbrel, Kevzara, and Xeljanz/Xeljanz XR*
3. Dose does not exceed 40 mg every other week.

**Approval duration: 12 months**

**H. Ulcerative Colitis** (must meet all):

1. Diagnosis of UC;
2. Dose does not exceed one of the following (a, b, or c):
  - a. For adults: 160 mg on Day 1 and 80 mg on Day 15, followed by maintenance dose of 40 mg every other week starting Day 29.
  - b. For pediatric patients weighing more than 20 kg, but less than 40 kg: 80 mg on Day 1, 40 mg on Day 8 and Day 15, followed by maintenance doses of 40 mg every other week or 20 mg every week
  - c. For pediatric patients weighing more than 40 kg: 160 mg on Day 1 and 80 mg on Day 8 and 15, followed by maintenance doses of 80 mg every other week or 40 mg every week.

**Approval duration: 12 months**

**I. Uveitis** (must meet all):

1. Diagnosis of non-infectious intermediate, posterior or panuveitis;
2. Failure of a  $\geq$  2 week trial of a systemic corticosteroid (e.g., prednisone) at up to maximally indicated doses, unless contraindicated or clinically significant adverse effects are experienced;

3. Failure of a trial of a non-biologic immunosuppressive therapy (e.g., azathioprine, methotrexate, mycophenolate mofetil, cyclosporine, tacrolimus, cyclophosphamide, chlorambucil) at up to maximally indicated doses, unless contraindicated or clinically significant adverse effects are experienced;
4. Dose does not exceed 80 mg initial dose, followed by maintenance dose of 40 mg every other week starting one week after initial dose.

**Approval duration: 12 months**

**J. Other diagnoses/indications**

1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.PMN.53 for Medicaid.

**II. Continued Therapy**

1. Member has 90 days of medication utilization.
2. If request is for a dose increase, new dose does not exceed one of the following (a, b, or c):
  - a. PJIA, PsA, AS, CD, PsO, UV: 40 mg every other week;
  - b. HS: 40 mg every week;
  - c. For UC, one of the following (i or ii)
    - i. 40 mg every other week or 20 mg every week;
    - ii. 80 mg every other week or 40 mg every week, and member initiated Humira prior to 18 years of age.

**Approval duration: 12 months\***

**III. Appendices/General Information**

*Appendix A: Abbreviation/Acronym Key*

6-MP: 6-mercaptopurine  
AS: ankylosing spondylitis  
CD: Crohn's disease  
CDAI: clinical disease activity index  
cJADAS: clinical juvenile arthritis disease activity score  
DMARD: disease-modifying antirheumatic drug  
FDA: Food and Drug Administration  
GI: gastrointestinal  
HS: hidradenitis suppurative  
MTX: methotrexate

NSAIDs: nonsteroidal anti-inflammatory drugs  
PJIA: polyarticular juvenile idiopathic arthritis  
PsA: psoriatic arthritis  
PsO: psoriasis  
RA: rheumatoid arthritis  
RAPID3: routine assessment of patient index data 3  
TNF: tumor necrosis factor  
UC: ulcerative colitis  
UV: uveitis

*Appendix B: Therapeutic Alternatives*

*This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.*

<b>Drug Name</b>	<b>Dosing Regimen</b>	<b>Dose Limit/ Maximum Dose</b>
acitretin (Soriatane <sup>®</sup> )	<b>PsO, HS</b> 25 or 50 mg PO QD	50 mg/day
azathioprine (Azasan <sup>®</sup> , Imuran <sup>®</sup> )	<b>RA</b> 1 mg/kg/day PO QD or divided BID  <b>CD*, UV*</b> 1.5 – 2 mg/kg/day PO	2.5 mg/kg/day
chlorambucil (Leukeran <sup>®</sup> )	<b>UV*</b> 0.2 mg/kg PO QD, then taper to 0.1 mg/kg PO QD or less	0.2 mg/kg/day
clindamycin (Cleocin <sup>®</sup> ) + rifampin (Rifadin <sup>®</sup> )	<b>HS*</b> clindamycin 300 mg PO BID and rifampin 300 mg PO BID	clindamycin: 1,800 mg/day rifampin: 600 mg/day
corticosteroids	<b>CD*</b> prednisone 40 mg PO QD for 2 weeks or IV 50 – 100 mg Q6H for 1 week  budesonide (Entocort EC <sup>®</sup> ) 6 – 9 mg PO QD  <b>UV*</b> prednisone 5 – 60 mg/day PO in 1 – 4 divided doses	Various
Cuprimine <sup>®</sup> (d-penicillamine)	<b>RA*</b> <u>Initial dose:</u> 125 or 250 mg PO QD <u>Maintenance dose:</u> 500 – 750 mg/day PO QD	1,500 mg/day
cyclophosphamide (Cytoxan <sup>®</sup> )	<b>UV*</b> 1 – 2 mg/kg/day PO	N/A
cyclosporine (Sandimmune <sup>®</sup> , Neoral <sup>®</sup> )	<b>PsO</b> 2.5 mg/kg/day PO divided BID  <b>RA</b> 2.5 – 4 mg/kg/day PO divided BID  <b>UV*</b> 2.5 – 5 mg/kg/day PO in divided doses	PsO, RA: 4 mg/kg/day  UV: 5 mg/kg/day
doxycycline (Acticlate <sup>®</sup> )	<b>HS*</b> 50 – 100 mg PO BID	300 mg/day
Hormonal agents	<b>HS</b>	varies

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
(e.g., estrogen-containing combined oral contraceptives, spironolactone)	varies	
hydroxychloroquine (Plaquenil®)	<b>RA*</b> <u>Initial dose:</u> 400 – 600 mg/day PO QD <u>Maintenance dose:</u> 200 – 400 mg/day PO QD	600 mg/day
Isotretinoin (Absorica®, Amnesteem®, Claravis®, Myorisan®, Zenatane®)	<b>HS</b> varies	varies 1.6 to 2 mg/kg/day
leflunomide (Arava®)	<b>PJIA*</b> Weight < 20 kg: 10 mg every other day PO Weight 20 - 40 kg: 10 mg/day PO Weight > 40 kg: 20 mg/day PO  <b>RA</b> 100 mg PO QD for 3 days, then 20 mg PO QD	20 mg/day
6-mercaptopurine (Purixan®)	<b>CD*</b> 50 mg PO QD or 1 – 2 mg/kg/day PO	2 mg/kg/day
methotrexate (Rheumatrex®)	<b>CD*</b> 15 – 25 mg/week IM or SC  <b>PsO</b> 10 – 25 mg/week PO or 2.5 mg PO Q12 hr for 3 doses/week  <b>PJIA*</b> 10 – 20 mg/m <sup>2</sup> /week PO, SC, or IM  <b>RA</b> 7.5 mg/week PO, SC, or IM or 2.5 mg PO Q12 hr for 3 doses/week  <b>UV*</b> 7.5 – 20 mg/week PO	30 mg/week
minocycline (Minocin®)	<b>HS*</b> 50 – 100 mg PO BID	200 mg/day
mycophenolate mofetil (Cellcept®)	<b>UV*</b> 500 – 1,000 mg PO BID	3 g/day

<b>Drug Name</b>	<b>Dosing Regimen</b>	<b>Dose Limit/ Maximum Dose</b>
NSAIDs (e.g., indomethacin, ibuprofen, naproxen, celecoxib)	<b>AS</b> Varies	Varies
Pentasa <sup>®</sup> (mesalamine)	<b>CD</b> 1,000 mg PO QID	4 g/day
Ridaura <sup>®</sup> (auranofin)	<b>RA</b> 6 mg PO QD or 3 mg PO BID	9 mg/day (3 mg TID)
sulfasalazine (Azulfidine <sup>®</sup> )	<b>PJIA*</b> 30-50 mg/kg/day PO divided BID  <b>RA</b> 2 g/day PO in divided doses	PJIA: 2 g/day  RA: 3 g/day  UC: 4 g/day
tacrolimus (Prograf <sup>®</sup> )	<b>CD*</b> 0.27 mg/kg/day PO in divided doses or 0.15 – 0.29 mg/kg/day PO  <b>UV*</b> 0.1-0.15 mg/kg/day PO	N/A
Enbrel <sup>®</sup> (etanercept)	<b>AS</b> 50 mg SC once weekly  <b>PJIA</b> Weight < 63 kg: 0.8 mg/kg SC once weekly Weight ≥ 63 kg: 50 mg SC once weekly  <b>PsA, RA</b> 25 mg SC twice weekly or 50 mg SC once weekly	50 mg/week
Cimzia <sup>®</sup> (certolizumab)	<b>AS</b> <u>Initial dose:</u> 400 mg SC at 0, 2, and 4 weeks <u>Maintenance dose:</u> 200 mg SC every other week (or 400 mg SC every 4 weeks)	400 mg every 4 weeks
Kevzara <sup>®</sup> (sarilumab)	<b>RA</b> 200 mg SC once every two weeks	200 mg/2 weeks
Otezla <sup>®</sup> (apremilast)	<b>PsA</b> <u>Initial dose:</u> Day 1: 10 mg PO QAM Day 2: 10 mg PO QAM and 10 mg PO QPM	60 mg/day



Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
	Day 3: 10 mg PO QAM and 20 mg PO QPM Day 4: 20 mg PO QAM and 20 mg PO QPM Day 5: 20 mg PO QAM and 30 mg PO QPM  <u>Maintenance dose:</u> Day 6 and thereafter: 30 mg PO BID	
Simponi <sup>®</sup> (golimumab)	<b>PsA</b> 50 mg SC once monthly	50 mg/month
Simponi Aria <sup>®</sup> (golimumab)	<b>PsA</b> <u>Initial dose:</u> 2 mg/kg IV at weeks 0 and 4 <u>Maintenance dose:</u> 2 mg/kg IV every 8 weeks	2 mg/kg every 8 weeks
Taltz <sup>®</sup> (ixekizumab)	<b>AS, PsA</b> <u>Initial dose:</u> 160 mg (two 80 mg injections) SC at week 0 <u>Maintenance dose:</u> 80 mg SC every 4 weeks  <b>PsO</b> <u>Initial dose:</u> 160 mg (two 80 mg injections) SC at week 0, then 80 mg SC at weeks 2, 4, 6, 8, 10, and 12 <u>Maintenance dose:</u> 80 mg SC every 4 weeks	80 mg every 4 weeks
Xeljanz <sup>®</sup> (tofacitinib)	<b>PsA, RA</b> 5 mg PO BID	10 mg/day
Xeljanz XR <sup>®</sup> (tofacitinib extended-release)	<b>PsA, RA</b> 11 mg PO QD	11 mg/day

Therapeutic alternatives are listed as Brand name<sup>®</sup> (generic) when the drug is available by brand name only and generic (Brand name<sup>®</sup>) when the drug is available by both brand and generic.

\*Off-label

Appendix C: Contraindications/Boxed Warnings

- Contraindication(s): none reported
- Boxed warning(s):
  - Serious infections
  - Malignancy

*Appendix D: General Information*

- Definition of failure of MTX or DMARDs
  - Child-bearing age is not considered a contraindication for use of MTX. Each drug has risks in pregnancy. An educated patient and family planning would allow use of MTX in patients who have no intention of immediate pregnancy.
  - Social use of alcohol is not considered a contraindication for use of MTX. MTX may only be contraindicated if patients choose to drink over 14 units of alcohol per week. However, excessive alcohol drinking can lead to worsening of the condition, so patients who are serious about clinical response to therapy should refrain from excessive alcohol consumption.
- Examples of positive response to therapy may include, but are not limited to:
  - Reduction in joint pain/swelling/tenderness
  - Improvement in ESR/CRP levels
  - Improvements in activities of daily living
- Hidradenitis suppurativa:
  - HS is sometimes referred to as: "acne inversa, acne conglobata, apocrine acne, apocrinitis, Fox-den disease, hidradenitis axillaris, HS, pyodermia sinifica fistulans, Velpau's disease, and Verneuil's disease."
  - In HS, Hurley stages are used to determine severity of disease. Hurley stage II indicates moderate disease, and is characterized by recurrent abscesses, with sinus tracts and scarring, presenting as single or multiple widely separated lesions. Hurley stage III indicates severe disease, and is characterized by diffuse or near-diffuse involvement presenting as multiple interconnected tracts and abscesses across an entire area.
- Ulcerative colitis: there is insufficient evidence to support the off-label weekly dosing of Humira for the treatment of moderate-to-severe UC. It is the position of Centene Corporation® that the off-label weekly dosing of Humira for the treatment of moderate-to-severe UC is investigational and not medically necessary at this time.
  - The evidence from the *post hoc* study of the Humira pivotal trial suggests further studies are needed to confirm the benefit of weekly Humira dosing for the treatment of UC in patients with inadequate or loss of therapeutic response to treatment with Humira every other week. No large, randomized or prospective studies have been published to support the efficacy of the higher frequency of dosing, while national and international treatment guidelines also do not strongly support dose escalation of Humira for UC. The current market consensus is that weekly dosing of Humira is not medically necessary due to lack of evidence to support its benefit.

*Appendix E: Immunomodulator Medical Justification*

- The following may be considered for medical justification supporting inability to use an immunomodulator for Crohn's disease:
  - Inability to induce short-term symptomatic remission with a 3-month trial of systemic glucocorticoids
  - High-risk factors for intestinal complications may include:
    - Initial extensive ileal, ileocolonic, or proximal GI involvement
    - Initial extensive perianal/severe rectal disease

- Fistulizing disease (e.g., perianal, enterocutaneous, and rectovaginal fistulas)
- Deep ulcerations
- Penetrating, stricturing or stenosis disease and/or phenotype
- Intestinal obstruction or abscess
- High risk factors for postoperative recurrence may include:
  - Less than 10 years duration between time of diagnosis and surgery
  - Disease location in the ileum and colon
  - Perianal fistula
  - Prior history of surgical resection
  - Use of corticosteroids prior to surgery

**IV. Dosage and Administration**

Indication	Dosing Regimen	Maximum Dose
RA	40 mg SC every other week  Some patients with RA not receiving concomitant methotrexate may benefit from increasing the frequency to 40 mg every week.	40 mg/week
PJIA	Weight 10 kg (22 lbs) to < 15 kg (33 lbs): 10 mg SC every other week Weight 15 kg (33 lbs) to < 30 kg (66 lbs): 20 mg SC every other week Weight ≥ 30 kg (66 lbs): 40 mg SC every other week	40 mg every other week
PsA AS	40 mg SC every other week	40 mg every other week
CD	<u>Initial dose:</u> <i>Adults:</i> 160 mg SC on Day 1, then 80 mg SC on Day 15  <i>Pediatrics:</i> Weight 17 kg (37 lbs) to < 40 kg (88 lbs): 80 mg SC on Day 1, then 40 mg SC on Day 15 Weight ≥ 40 kg (88 lbs): 160 mg SC on Day 1, then 80 mg SC on Day 15  <u>Maintenance dose:</u> <i>Adults:</i> 40 mg SC every other week starting on Day 29  <i>Pediatrics:</i> Weight 17 kg (37 lbs) to < 40 kg (88 lbs): 20 mg SC every other week starting on Day 29	40 mg every other week

Indication	Dosing Regimen	Maximum Dose												
	Weight $\geq$ 40 kg (88 lbs): 40 mg SC every other week starting on Day 29													
UC	<p><u>Initial dose:</u>  <i>Adults:</i> 160 mg SC on Day 1, then 80 mg SC on Day 15</p> <p><i>Pediatrics:</i></p> <table border="1" data-bbox="492 531 1058 865"> <thead> <tr> <th data-bbox="492 531 688 569">Weight</th> <th data-bbox="688 531 1058 569">Days 1 through 15</th> </tr> </thead> <tbody> <tr> <td data-bbox="492 569 688 680">20 kg to less than 40 kg</td> <td data-bbox="688 569 1058 680">Day 1: 80 mg Day 8: 40 mg Day 15: 40 mg</td> </tr> <tr> <td data-bbox="492 680 688 865">40 kg and greater</td> <td data-bbox="688 680 1058 865">Day 1: 160 mg (single dose or split over tw consecutive days) Day 8: 80 mg Day 15: 80 mg</td> </tr> </tbody> </table> <p><u>Maintenance dose:</u>  <i>Adults:</i> 40 mg SC every other week starting on Day 29</p> <p><i>Pediatrics:</i></p> <table border="1" data-bbox="492 1050 1058 1236"> <thead> <tr> <th data-bbox="492 1050 688 1087">Weight</th> <th data-bbox="688 1050 1058 1087">Starting on Day 29*</th> </tr> </thead> <tbody> <tr> <td data-bbox="492 1087 688 1163">20 kg to less than 40 kg</td> <td data-bbox="688 1087 1058 1163">40 mg every other week or 20 mg every week</td> </tr> <tr> <td data-bbox="492 1163 688 1236">40 kg and greater</td> <td data-bbox="688 1163 1058 1236">80 mg every other week or 40 mg every week</td> </tr> </tbody> </table> <p><i>*Continue the recommended pediatric dosage in patients who turn 18 years of age and who are well-controlled on Humira regimen.</i></p>	Weight	Days 1 through 15	20 kg to less than 40 kg	Day 1: 80 mg Day 8: 40 mg Day 15: 40 mg	40 kg and greater	Day 1: 160 mg (single dose or split over tw consecutive days) Day 8: 80 mg Day 15: 80 mg	Weight	Starting on Day 29*	20 kg to less than 40 kg	40 mg every other week or 20 mg every week	40 kg and greater	80 mg every other week or 40 mg every week	40 mg every week
Weight	Days 1 through 15													
20 kg to less than 40 kg	Day 1: 80 mg Day 8: 40 mg Day 15: 40 mg													
40 kg and greater	Day 1: 160 mg (single dose or split over tw consecutive days) Day 8: 80 mg Day 15: 80 mg													
Weight	Starting on Day 29*													
20 kg to less than 40 kg	40 mg every other week or 20 mg every week													
40 kg and greater	80 mg every other week or 40 mg every week													
PsO	<p><u>Initial dose:</u> 80 mg SC</p> <p><u>Maintenance dose:</u> 40 mg SC every other week starting one week after initial dose</p>	40 mg every other week												
UV	<p><i>Pediatrics:</i>            Weight 10 kg (22 lbs) to &lt; 15 kg (33 lbs): 10 mg SC every other week            Weight 15 kg (33 lbs) to &lt; 30 kg (66 lbs): 20 mg SC every other week            Weight <math>\geq</math> 30 kg (66 lbs): 40 mg SC every other week</p> <p><i>Adults:</i>            Initial dose of 80 mg SC, followed by 40 mg SC every other week starting one week after the initial dose</p>	40 mg every other week												

Indication	Dosing Regimen	Maximum Dose
HS	<p><i>For patients 12 years of age and older weighing at least 30 kg:</i></p> <p><u>Initial dose:</u> Weight 30 kg (66 lbs) to &lt; 60 kg (132 lbs): 80 mg SC on Day 1, then 40 mg on Day 8 Weight ≥ 60 kg (132 lbs): 160 mg SC on Day 1, then 80 mg SC on Day 15</p> <p><u>Maintenance dose:</u> Weight 30 kg (66 lbs) to &lt; 60 kg (132 lbs): 40 mg every other week Weight ≥ 60 kg (132 lbs): 40 mg SC once weekly starting on Day 29</p>	40 mg/week

**V. Product Availability**

Drug Name	Availability
adalimumab (Humira)	<ul style="list-style-type: none"> <li>• Single-dose prefilled pen: 80 mg/0.8 mL, 40 mg/0.8 mL, 40 mg/0.4 mL</li> <li>• Single-dose prefilled syringe: 80 mg/0.8 mL, 40 mg/0.8 mL, 40 mg/0.4 mL, 20 mg/0.4 mL, 20 mg/0.2 mL, 10 mg/0.2 mL, 10 mg/0.1 mL</li> <li>• Single-use vial for institutional use only: 40 mg/0.8 mL</li> </ul>
Adalimumab-atto (Amjevita)	<ul style="list-style-type: none"> <li>• Single-dose prefilled SureClick autoinjector: 40 mg/0.8 mL</li> <li>• Single-dose prefilled syringe: 40 mg/0.8 mL, 20 mg/0.4 mL</li> </ul>
Adalimumab-adbm (Cyltezo)	<ul style="list-style-type: none"> <li>• Single-dose prefilled syringe: 40 mg/0.8 mL, 20 mg/0.4 mL</li> </ul>
Adalimumab-bwwd (Hadlima)	<ul style="list-style-type: none"> <li>• Single-dose prefilled PushTouch autoinjector: 40 mg/0.8 mL</li> <li>• Single-dose prefilled syringe: 40 mg/0.8 mL</li> </ul>
Adalimumab-adaz (Hyrimoz)	<ul style="list-style-type: none"> <li>• Single-dose prefilled glass syringe (with BD UltraSafe Passive™ Needle Guard): 40 mg/0.8 mL</li> <li>• Single-dose prefilled pen (Sensoready® Pen): 40 mg/0.8 mL</li> </ul>

**VI. References**

1. Humira Prescribing Information. North Chicago, IL: AbbVie, Inc.; February 2021. Available at: <https://www.humira.com>. Accessed March 3, 2021.
2. Amjevita Prescribing Information. Thousand Oaks, CA: Amgen Inc.; June 2019. Available at: [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2019/761024s004lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761024s004lbl.pdf). Accessed January 15, 2021.

**Coding Implications**

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-

date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

HCPCS Codes	Description
J0135	Injection, adalimumab, 20 mg

Reviews, Revisions, and Approvals	Date	P&T Approval Date
Created PA Alignment for IN Medicaid.	08.21	OMPP
Annual Review. No Changes	10.22	

**Important Reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to

recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

**Note:**

**For Medicaid members**, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2016 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.